TILT Biotherapeutics Ltd is a preclinical stage company working in the field of cancer immunotherapy. TILT aims to translate its unique approach into clinical trials. The company’s patented technology involves utilization of oncolytic viruses for enhancement of tumor T-cell therapy. Initial embodiments of the technology will be used to enhance tumor infiltrating lymphocyte (TIL), chimeric antigen receptor (CAR) and checkpoint inhibiting antibody therapy. The TILT approach has the potential to achieve similar results in CAR therapy of solid tumors as currently achieved for CD19+ hematological tumors.
|Employees (est.) (May 2020)||11|
Tilt Biotherapeutics total Funding
Tilt Biotherapeutics latest funding size
Time since last funding
|3 years ago|
When was Tilt Biotherapeutics founded?
Tilt Biotherapeutics was founded in 2013.
How many employees does Tilt Biotherapeutics have?
Tilt Biotherapeutics has 11 employees.
Who are Tilt Biotherapeutics competitors?
Competitors of Tilt Biotherapeutics include Clementia Pharmaceuticals, DBV Technologies and Synthace.
Where is Tilt Biotherapeutics headquarters?
Tilt Biotherapeutics headquarters is located at 3 Haartmaninkatu, Helsinki.
Where are Tilt Biotherapeutics offices?
Tilt Biotherapeutics has an office in Helsinki.
How many offices does Tilt Biotherapeutics have?
Tilt Biotherapeutics has 1 office.
Receive alerts for 300+ data fields across thousands of companies